Alnylam to Webcast Conference Call Discussing Second Quarter 2025 Financial ResultsBusiness Wire • 07/17/25
Alnylam Announces Promotion of Pushkal Garg to Chief Research and Development OfficerBusiness Wire • 06/18/25
Alnylam Receives European Commission Approval for AMVUTTRA® (vutrisiran) for the Treatment of ATTR Amyloidosis with CardiomyopathyBusiness Wire • 06/09/25
Alnylam to Webcast Presentation at Goldman Sachs 46th Annual Global Healthcare ConferenceBusiness Wire • 05/28/25
AMVUTTRA® (vutrisiran) Significantly Reduces Mortality and a Range of Important Cardiovascular Events in Patients with ATTR Amyloidosis with Cardiomyopathy: Additional Data from HELIOS-BBusiness Wire • 05/17/25
Alnylam to Share Progress Across its Transthyretin Amyloidosis Franchise Including Additional Analyses of the HELIOS-B Phase 3 Study Results at Heart Failure 2025 CongressBusiness Wire • 05/12/25
Alnylam to Webcast Presentation at BofA Securities 2025 Health Care ConferenceBusiness Wire • 05/05/25
Compared to Estimates, Alnylam (ALNY) Q1 Earnings: A Look at Key MetricsZacks Investment Research • 05/01/25
Alnylam Pharmaceuticals (ALNY) Reports Q1 Loss, Tops Revenue EstimatesZacks Investment Research • 05/01/25
Alnylam Pharmaceuticals Reports First Quarter 2025 Financial Results and Highlights Recent Period ProgressBusiness Wire • 05/01/25
Seeking Clues to Alnylam (ALNY) Q1 Earnings? A Peek Into Wall Street Projections for Key MetricsZacks Investment Research • 04/29/25
Alnylam Receives Positive CHMP Opinion for Vutrisiran for the Treatment of ATTR Amyloidosis with CardiomyopathyBusiness Wire • 04/28/25
Earnings Preview: Alnylam Pharmaceuticals (ALNY) Q1 Earnings Expected to DeclineZacks Investment Research • 04/24/25
Alnylam to Webcast Conference Call Discussing First Quarter 2025 Financial ResultsBusiness Wire • 04/17/25
Alnylam to Webcast Presentation at Needham 24th Annual Virtual Healthcare ConferenceBusiness Wire • 04/01/25
Alnylam Presents New Data from the HELIOS-B Phase 3 Study of Vutrisiran in Patients with ATTR Amyloidosis with Cardiomyopathy (ATTR-CM) at the American College of Cardiology's Annual Scientific Session 2025Business Wire • 03/29/25